NATIONAL CENTER FOR **IMMUNIZATION & RESPIRATORY DISEASES**

Bacterial and viral infections among hospitalized adults with COVID-19, COVID-NET, 14 states, March 2020–April 2022

Melisa M. Shah, MD, MPH^{1,2}; Kadam Patel, MPH^{2,3,4}; Jennifer Milucky, MSPH^{2,4}; Christopher A. Taylor, PhD^{2,4}; Arthur Reingold, MD⁶; Isaac Armistead, MD, MPH⁷; James Meek, MPH⁸; Evan J. Anderson, MD⁹; Andy Weigel, MSW¹⁰; Libby Reeg, MPH¹¹; Kathryn Como-Sabetti, MPH¹²; Susan L. Ropp, PhD¹³; Alison Muse, MPH¹⁴; Sophrena Bushey, MHS¹⁵; Eli Shiltz, MPH¹⁶; Melissa Sutton, MD, MPH¹⁷; H. Keipp Talbot, MD, MPH¹⁸; Ryan Chatelain, MPH¹⁹; Fiona P. Havers, MD, MHS^{2,3,5}; on behalf of the CDC COVID-NET Surveillance Team

BACKGROUND

- Bacterial and viral coinfections occur with viral respiratory tract infections and can be associated with increased morbidity/mortality
- Compared to previous influenza pandemics, a low proportion of COVID-19 patients have been reported to have bacterial coinfections
- Prevalence, risk factors, and associated clinical outcomes in patients with bacterial/viral coinfections with SARS-CoV-2 are not fully understood.

Objectives:

- 1) To describe the prevalence of bacterial and viral coinfections in hospitalized adults with COVID-19 using a population-based surveillance system
- 1) To examine the association of bacterial coinfection with mortality among hospitalized adults with COVID-19

METHODS

- Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system, used to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection between March 2020 and April 2022
- Clinician-driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites included
- Prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non-SARS-CoV-2 endemic coronaviruses described
- Multivariable logistic regression with generalized estimating equations (GEE) and controlling for underlying medical condition, age, sex, and race/ethnicity used to examine the association of bacterial coinfection and severe outcomes

RESULTS

- Among 36,490 hospitalized adults with COVID-19, 53.3% had bacterial cultures taken within 7 days of admission; 6.0% of those tested had a clinically relevant bacterial infection (Table 1)
- *Staphylococcus aureus* and Gram-negative rods were most frequently isolated (Figure 1)
- Bacterial infections in COVID-19 patients within 7 days of admission associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing (Table 2)
- Among hospitalized adults with COVID-19, 2,766 (7.6%) tested for all 7 virus groups; a non-SARS-CoV-2 virus was identified in 0.9%

Bacterial coinfections within 7 days of admission were identified in 6% of hospitalized adults with **COVID-19 and** were associated with increased mortality.

TABLE 1:

Baseline characteristics of hospitalized adults with COVID-19 and bacterial testing performed within 7 days of admission, COVID-NET March 2020–April 2022, stratified by presence of bacterial infections

	Clinically relevant bacterial infection within ±7 days of admission admission among those wit bacterial culture performed		
	Weighted column % with 95% Cl	Weighted column % with 95% CI	
	n=1,140	n=17,236	
Sex			
Male	58.2 (53.2-63.1)	53.7 (52.3-55.0)	
Female	41.8 (36.9-46.8)	46.3 (45.0-47.7)	
Age category			
18-34 years	6.0 (4.1-8.6)	7.4 (6.8-8.1)	
35-54 years	22.9 (19.2-27.0)	23.4 (22.3-24.4) 42.0 (40.7-43.3)	
55-74 years	44.0 (39.1-49.0)		
75+ years	27.0 (22.6-31.8)	27.2 (25.9-28.6)	
Race/ethnicity			
Non-Hispanic White	49.2 (44.1-54.3)	49.0 (47.6-50.4)	
Non-Hispanic Black	29.3 (24.6-34.4)	26.6 (25.3-27.8)	
Non-Hispanic AI/AN	2.1 (1.1-3.5)	1.6 (1.3-1.9)	
Asian/Pacific Islander	4.0 (2.4-6.2)	5.9 (5.2-6.8)	
Hispanic	15.4 (12.1-19.1)	16.9 (16.0-17.9)	
Any Underlying Condition	96.3 (94.6-97.5)	91.8 (91.1-92.5)	
Outcomes			
Intensive Care Required	60.0 (54.9-64.9)	28.5 (27.3-29.7)	
Mechanical Ventilation	47.6 (42.6-52.6)	15.6 (14.7-16.6)	
Death	31.7 (27.2-36.5)	13.2 (12.3-14.1)	

AI/AN = American Indian/Alaska Native

TABLE 2:

Adjusted relative risk for death among hospitalized adults with COVID-19 who had bacterial testing performed within 7 days of admission, COVID-NET March 2020–April 2022

	Adjusted Relative Risk for Death (95% Cl) n=16,383	p-value
Bacterial infection in a respiratory or sterile		
site within 7 days of hospital admission	2.28 (1.86, 2.80)	<0.01
Sex		
Male	1.19 (0.99, 1.43)	0.06
Female	Ref	Ref
Age Category		
18-34 years	Ref	Ref
35-54 years	1.68 (1.14, 2.49)	0.01
55-74 years	3.95 (2.40, 6.52)	<0.01
75 years or more	5.54 (3.31, 9.28)	<0.01
Race/Ethnicity		
Non-Hispanic White	Ref	Ref
Non-Hispanic Black	0.98 (0.86, 1.12)	0.80
Non-Hispanic AI/AN	1.19 (0.91, 1.54)	0.21
Asian/Pacific Islander	1.21 (1.05, 1.41)	0.01
Hispanic	1.38 (1.12, 1.69)	<0.01
Chronic Lung Disease	0.95 (0.80, 1.12)	0.55
Diabetes	1.06 (0.93, 1.19)	0.39
Cardiovascular Disease	1.24 (1.05, 1.47)	0.01
Obesity	1.12 (0.96, 1.31)	0.15
Gastrointestinal/Liver Disease	0.83 (0.64, 1.08)	0.17
Renal Disease	1.26 (1.14, 1.39)	<0.01

FIGURE 1:

Bacterial pathogens recovered within 7 days of admission from sputum, deep respiratory, and blood specimens among hospitalized adults with COVID-19 from March 2020 to April 2022. Figure includes 1,408 bacterial cultures from 1,066 individuals. Deep respiratory sites include endotracheal aspirate, bronchoalveolar lavage fluid, pleural fluid, and lung tissue. Unweighted counts and percentages are reported.

Staphylococcus aureus Pseudomonas aeruginosa Klebsiella pneumoniae Haemophilus influenzae Escherichia coli Serratia marcescens Enterobacter aerogenes Other Gram-Negative Ro

Staphylococcus aureus Pseudomonas aeruginosa Escherichia coli Klebsiella pneumoniae laemophilus influenzae Group B streptococcus Enterobacter cloacae Other Gram-Negative Rod

taphylococcus aureus Klehsiella nneumoniae Proteus mirabilis Group B streptococcus Pseudomonas aeruginos Other Gram-Negative Rod Other

CONCLUSIONS

• Among patients with clinician-driven testing, 6.0% of hospitalized adults with COVID-19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections.

% of Positive Blood Cultures


20 25 30 35 40 45

• Identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; ²COVID-19 Emergency Response Team enters for Disease Control and Prevention. Atlanta, GA, USA: ³General Dynamics Information Technology, Atlanta, GA, USA: ⁴Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, Division for Viral Diseases, National Center for nmunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; ⁵US Public Health Service Commissioned Corps, Rockville, MD, USA; ⁶University of California, Berkely, Berkely, CA; California Emerging Infections Program Dakland, CA, USA; ⁷Colorado Department of Public Health & Environment, Denver, CO, USA; ⁸Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, USA; ⁹Departments of Medicine and Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA; ¹⁰Iowa Department of Health, Des Moines, IA, USA; ¹¹Michigan Department of Health and Human Services, Lansing, MI, USA; ¹²Minnesota Department of Health, USA; ¹³New Mexico Department of Health, Santa Fe, NM, USA; ¹⁴New York State Department of Health, Albany, NY, USA; ¹⁵University of Rochester School of Medicine and Dentistry Rochester, NY, USA; ¹⁶Ohio Department of Health, USA. ¹⁷Public Health Division, Oregon Health Authority; Portland, OR, USA Vanderbilt University Medical Center, Nashville, TN, USA; 19Salt Lake County Health Department, Salt Lake City, UT, USA

AI/AN = American Indian/Alaska Native

Bacteria Cultured from Sputum Specimens n=452



CONTACT INFO Melisa M. Shah bgn3@cdc.gov

